

Yihua Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8319784/publications.pdf>

Version: 2024-02-01

62
papers

2,427
citations

201385

27
h-index

205818

48
g-index

66
all docs

66
docs citations

66
times ranked

3135
citing authors

#	ARTICLE	IF	CITATIONS
1	Protein S-Nitrosation: Biochemistry, Identification, Molecular Mechanisms, and Therapeutic Applications. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 5902-5925.	2.9	17
2	Synthesis and biological evaluation of hybrids from optically active ring-opened 3-N-butylphthalide derivatives and 4-fluoro-edaravone as potential anti-acute ischemic stroke agents. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 69, 116891.	1.4	3
3	Design, Synthesis, and Biological Evaluation of Organic Nitrite (NO ₂ ⁺) Donors as Potential Anticerebral Ischemia Agents. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10919-10933.	2.9	7
4	Tetrazine-mediated bioorthogonal removal of 3-isocyanopropyl groups enables the controlled release of nitric oxide <i>in vivo</i> . <i>Biomaterials Science</i> , 2021, 9, 1816-1825.	2.6	6
5	From Seeds of <i>Apium graveolens</i> Linn. to a Cerebral Ischemia Medicine: The Long Journey of 3-N-Butylphthalide. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12485-12510.	2.9	21
6	Identification of New Nitric Oxide-Donating Peptides with Dual Biofilm Eradication and Antibacterial Activities for Intervention of Device-Related Infections. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9127-9135.	2.9	30
7	General Strategy for Integrated Bioorthogonal Prodrugs: Pt(II)-Triggered Depropargylation Enables Controllable Drug Activation <i>In Vivo</i> . <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13899-13912.	2.9	22
8	New techniques and strategies in drug discovery. <i>Chinese Chemical Letters</i> , 2020, 31, 1695-1708.	4.8	82
9	Design and synthesis of the ring-opened derivative of 3-n-butylphthalide-ferulic acid-glucose trihybrids as potential anti-ischemic agents. <i>Chinese Chemical Letters</i> , 2020, 31, 1881-1886.	4.8	10
10	Effective Virtual Screening Strategy toward heme-containing proteins: Identification of novel IDO1 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 184, 111750.	2.6	15
11	Anti-CD24 Antibody-Nitric Oxide Conjugate Selectively and Potently Suppresses Hepatic Carcinoma. <i>Cancer Research</i> , 2019, 79, 3395-3405.	0.4	39
12	Nanoscale Coordination Polymers for Synergistic NO and Chemodynamic Therapy of Liver Cancer. <i>Nano Letters</i> , 2019, 19, 2731-2738.	4.5	158
13	Design and synthesis of rosiglitazone-ferulic acid-nitric oxide donor trihybrids for improving glucose tolerance. <i>European Journal of Medicinal Chemistry</i> , 2019, 162, 650-665.	2.6	6
14	Design and synthesis of new hybrids from 2-cyano-3,12-dioxooleana-9-dien-28-oic acid and O ² -(2,4-dinitrophenyl) diazeniumdiolate for intervention of drug-resistant lung cancer. <i>European Journal of Medicinal Chemistry</i> , 2018, 149, 269-280.	2.6	20
15	Identification of a Novel Hybridization from Isosorbide 5-Mononitrate and Bardoxolone Methyl with Dual Activities of Pulmonary Vasodilation and Vascular Remodeling Inhibition on Pulmonary Arterial Hypertension Rats. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1474-1482.	2.9	20
16	Glutathione S-Transferase-Activatable O ² -(Sulfonyl ethyl Derived) Diazeniumdiolates Potently Suppress Melanoma <i>In Vitro</i> and <i>In Vivo</i> . <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1833-1844.	2.9	17
17	Novel Ligustrazine-Based Analogs of Piperlongumine Potently Suppress Proliferation and Metastasis of Colorectal Cancer Cells <i>In Vitro</i> and <i>In Vivo</i> . <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1821-1832.	2.9	45
18	Synthesis and Evaluation of O ² -Derived Diazeniumdiolates Activatable via Bioorthogonal Chemistry Reactions in Living Cells. <i>Organic Letters</i> , 2018, 20, 2164-2167.	2.4	21

#	ARTICLE	IF	CITATIONS
19	8e Protects against Acute Cerebral Ischemia by Inhibition of PI3K ^β -Mediated Superoxide Generation in Microglia. <i>Molecules</i> , 2018, 23, 2828.	1.7	11
20	<i>O</i> ² -3-Aminopropyl diazeniumdiolates suppress the progression of highly metastatic triple-negative breast cancer by inhibition of microvesicle formation <i>via</i> nitric oxide-based epigenetic regulation. <i>Chemical Science</i> , 2018, 9, 6893-6898.	3.7	20
21	Dual Intratumoral Redox/Enzyme-Responsive NO-Releasing Nanomedicine for the Specific, High-Efficacy, and Low-Toxic Cancer Therapy. <i>Advanced Materials</i> , 2018, 30, e1704490.	11.1	155
22	Potent Inhibition of Nitric Oxide-Releasing Bifendate Derivatives against Drug-Resistant K562/A02 Cells in Vitro and in Vivo. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 928-940.	2.9	32
23	<i>O</i> ² -(6-Oxocyclohex-1-en-1-yl)methyl diazen-1-ium-1,2-diolates: a new class of nitric oxide donors activatable by GSH/GST with both anti-proliferative and anti-metastatic activities against melanoma. <i>Chemical Communications</i> , 2017, 53, 5059-5062.	2.2	13
24	Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7617-7635.	2.9	260
25	Systematic study of imidazoles inhibiting IDO1 via the integration of molecular mechanics and quantum mechanics calculations. <i>European Journal of Medicinal Chemistry</i> , 2017, 131, 152-170.	2.6	13
26	Novel Derivative of Bardoxolone Methyl Improves Safety for the Treatment of Diabetic Nephropathy. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8847-8857.	2.9	29
27	Synthesis and evaluation of novel <i>O</i> ² -derived diazeniumdiolates as photochemical and real-time monitoring nitric oxide delivery agents. <i>Organic Chemistry Frontiers</i> , 2017, 4, 2445-2449.	2.3	16
28	Discovery of phosphorodiamidate mustard-based O ² -phosphorylated diazeniumdiolates with potent anticancer activity. <i>RSC Advances</i> , 2017, 7, 18893-18899.	1.7	5
29	Discovery of potent IDO1 inhibitors derived from tryptophan using scaffold-hopping and structure-based design approaches. <i>European Journal of Medicinal Chemistry</i> , 2017, 138, 199-211.	2.6	14
30	Synthesis and evaluation of N-heteroaromatic ring-based analogs of piperlongumine as potent anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2017, 138, 313-319.	2.6	26
31	Enantiomers of 3-pentylbenzo[c]thiophen-1(3H)-one: preparation and evaluation of anti-ischemic stroke activities. <i>RSC Advances</i> , 2016, 6, 36888-36897.	1.7	4
32	Discovery of a ring-opened derivative of 3-n-butylphthalide bearing NO/H ₂ S-donating moieties as a potential anti-ischemic stroke agent. <i>European Journal of Medicinal Chemistry</i> , 2016, 115, 369-380.	2.6	29
33	Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2795-2800.	1.0	31
34	Design, Synthesis, and Evaluation of Diazeniumdiolate-Based DNA Cross-Linking Agents Activatable by Glutathione S-Transferase. <i>Organic Letters</i> , 2016, 18, 5196-5199.	2.4	14
35	Anticancer efficacy of a nitric oxide-modified derivative of bifendate against multidrug-resistant cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 1095-1105.	1.6	30
36	Synthesis and Biological Evaluation of Novel Olean-28,13 ^β -lactams as Potential Antiprostata Cancer Agents. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4506-4520.	2.9	27

#	ARTICLE	IF	CITATIONS
37	Identification of nitric oxide-releasing derivatives of oleanolic acid as potential anti-colon cancer agents. <i>RSC Advances</i> , 2015, 5, 19445-19454.	1.7	9
38	Synthesis of CDDO-“Amino Acid”-Nitric Oxide Donor Trihybrids as Potential Antitumor Agents against Both Drug-Sensitive and Drug-Resistant Colon Cancer. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2452-2464.	2.9	65
39	The protective effect of CDDO-Me on lipopolysaccharide-induced acute lung injury in mice. <i>International Immunopharmacology</i> , 2015, 25, 55-64.	1.7	143
40	Novel hybrids of 3-n-butylphthalide and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3535-3540.	1.0	33
41	5d, a novel analogue of 3-n-butylphthalide, protects brains against nervous injury induced by ischemia/reperfusion through Akt/Nrf2/NOX4 signaling pathway. <i>RSC Advances</i> , 2015, 5, 69583-69592.	1.7	6
42	(S)-ZJM-289 Preconditioning Induces a Late Phase Protection Against Nervous Injury Induced by Transient Cerebral Ischemia and Oxygen-Glucose Deprivation. <i>Neurotoxicity Research</i> , 2014, 26, 16-31.	1.3	16
43	Design, synthesis and biological evaluation of hydrogen sulfide releasing derivatives of 3-n-butylphthalide as potential antiplatelet and antithrombotic agents. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 5995-6004.	1.5	26
44	Synthesis and biological evaluation of nitric oxide releasing derivatives of 6-amino-3-n-butylphthalide as potential antiplatelet agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1985-1988.	1.0	18
45	Novel Hybrids of Optically Active Ring-Opened 3-n-Butylphthalide Derivative and Isosorbide as Potential Anti-Ischemic Stroke Agents. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3078-3089.	2.9	38
46	Novel Hybrids of (Phenylsulfonyl)furoxan and Anilinopyrimidine as Potent and Selective Epidermal Growth Factor Receptor Inhibitors for Intervention of Non-Small-Cell Lung Cancer. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4738-4748.	2.9	67
47	Hybrid Molecule from O^{2-} -(2,4-Dinitrophenyl)diazoniumdiolate and Oleanolic Acid: A Glutathione S-Transferase γ -Activated Nitric Oxide Prodrug with Selective Anti-Human Hepatocellular Carcinoma Activity and Improved Stability. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4641-4655.	2.9	55
48	Synthesis and Biological Evaluation of Novel Furozan-Based Nitric Oxide-Releasing Derivatives of Oridonin as Potential Anti-Tumor Agents. <i>Molecules</i> , 2012, 17, 7556-7568.	1.7	33
49	Discovery of a Potential Anti-Ischemic Stroke Agent: 3-Pentylbenzo[<i>c</i>]thiophen-1(3 <i>H</i>)-one. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7173-7181.	2.9	44
50	Studies on the enantiomers of ZJM-289: synthesis and biological evaluation of antiplatelet, antithrombotic and neuroprotective activities. <i>Organic and Biomolecular Chemistry</i> , 2012, 10, 9030.	1.5	14
51	Glycosylated diazeniumdiolate-based oleanolic acid derivatives: synthesis, in vitro and in vivo biological evaluation as anti-human hepatocellular carcinoma agents. <i>Organic and Biomolecular Chemistry</i> , 2012, 10, 3882.	1.5	22
52	O^{2-} -Sulfonylethyl Protected Isopropylamine Diazen-1-ium-1,2-diulates as Nitroxyl (HNO) Donors: Synthesis, β -Elimination Fragmentation, HNO Release, Positive Inotropic Properties, and Blood Pressure Lowering Studies. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10262-10271.	2.9	19
53	(S)-ZJM-289, a nitric oxide-releasing derivative of 3-n-butylphthalide, protects against ischemic neuronal injury by attenuating mitochondrial dysfunction and associated cell death. <i>Neurochemistry International</i> , 2012, 60, 134-144.	1.9	40
54	Tacrine-“Ferulic Acid”-Nitric Oxide (NO) Donor Trihybrids as Potent, Multifunctional Acetyl- and Butyrylcholinesterase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4309-4321.	2.9	122

#	ARTICLE	IF	CITATIONS
55	Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potent P-glycoprotein inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2012, 51, 137-144.	2.6	31
56	Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 801-805.	1.0	17
57	Design, synthesis and evaluation of nitric oxide releasing derivatives of 3-n-butylphthalide as antiplatelet and antithrombotic agents. <i>Organic and Biomolecular Chemistry</i> , 2011, 9, 5670.	1.5	37
58	Novel Nitric Oxide-Releasing Derivatives of Farnesylthiosalicylic Acid: Synthesis and Evaluation of Antihepatocellular Carcinoma Activity. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 3251-3259.	2.9	61
59	Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 3448-3456.	1.4	37
60	Synthesis and biological evaluation of furoxan-based nitric oxide-releasing derivatives of glycyrrhetic acid as anti-hepatocellular carcinoma agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 6416-6420.	1.0	45
61	Synthesis and anti-human hepatocellular carcinoma activity of new nitric oxide-releasing glycosyl derivatives of oleanolic acid. <i>Organic and Biomolecular Chemistry</i> , 2010, 8, 632-639.	1.5	49
62	Design, Synthesis, and Antihepatocellular Carcinoma Activity of Nitric Oxide Releasing Derivatives of Oleanolic Acid. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4834-4838.	2.9	97